nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients

Ueno, M; Nakamori, S; Sugimori, K; Kanai, M; Ikeda, M; Ozaka, M; Furukawa, M; Okusaka, T; Kawabe, K; Furuse, J; Komatsu, Y; Ishii, H; Sato, A; Shimizu, S; Chugh, P; Tang, R; Ioka, T

Ueno, M (corresponding author), Kanagawa Canc Ctr, Dept Gastroenterol Hepatobiliary & Pancreat Med, Div Oncol, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2418515, Japan.

CANCER MEDICINE, 2020; 9 (24): 9396

Abstract

Background In the NAPOLI-1 phase 3 trial, liposomal irinotecan (nal-IRI) +5-fluorouracil/leucovorin (5-FU/LV) significantly increased mPFS versus 5-FU......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索